News Sentiment

2696 sentiment intelligence

Shanghai Henlius Biotech, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 51 Balanced news tone 10 relevant articles
Exchange HKG Hong Kong
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 62.90 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

88/100 classification confidence.

Company focus 10

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.7% over one week, +0.5% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Shanghai Henlius Biotech (SEHK:2696) Advances Cancer Trials, Is It A Bargain?

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 88/100 classification
One-week reaction -5.7% Price reacting lower
Trend fit Trend inactive 0.5% over four weeks
Fair value 68.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 9
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 10
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
simplywall.st 2
Fierce Pharma 2
South China Morning Post 2
Market source 1
hkex.com.hk 1
Reuters 1
Caixin Global 1

Event Lens

What the news is about

Classified themes
Market update 8
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-10 of 10